Virtu Financial LLC Sells 1,026 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Virtu Financial LLC decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 13.5% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,561 shares of the biopharmaceutical company’s stock after selling 1,026 shares during the period. Virtu Financial LLC’s holdings in Halozyme Therapeutics were worth $314,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Heck Capital Advisors LLC purchased a new position in Halozyme Therapeutics during the 4th quarter valued at about $29,000. CBIZ Investment Advisory Services LLC purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. Smartleaf Asset Management LLC raised its holdings in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company’s stock valued at $42,000 after acquiring an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter worth $69,000. Finally, Parkside Financial Bank & Trust boosted its holdings in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 322 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Price Performance

NASDAQ HALO opened at $64.48 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The company has a market capitalization of $7.97 billion, a price-to-earnings ratio of 18.80, a PEG ratio of 0.42 and a beta of 1.32. The stock has a 50-day moving average of $58.98 and a 200 day moving average of $54.85. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.02. The firm had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Insider Buying and Selling

In related news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $58.69, for a total transaction of $293,450.00. Following the completion of the transaction, the director now owns 33,611 shares of the company’s stock, valued at approximately $1,972,629.59. The trade was a 12.95 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,697 shares of company stock valued at $1,754,451. 2.40% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on HALO shares. Wells Fargo & Company reduced their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Benchmark reaffirmed a “buy” rating and issued a $75.00 price target on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.